Thermo Fisher Scientific Inc., has announced that the U.S. Food and Drug Administration (FDA) has further expanded emergency use authorization (EUA) for its multiplex real-time PCR test intended for the qualitative detection of nucleic acid from SARS?CoV?2, the virus that causes COVID-19. "Increasing COVID-19 testing is a top priority in re-opening global economies," said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific....
The Wyss Institute for Biologically Inspired Engineering at Harvard University and Cytosurge AG, a company manufacturing unique high-precision nanotechnology instruments, have announced that they will collaboratively investigate CRISPR-based approaches to more effectively introduce multiple edits into the genome of single cells, while minimizing CRISPR-related toxicity. This capability could become instrumental in driving forward diverse large-scale efforts such as...
Data scientists from UK-headquartered AI precision medicine company, PrecisionLife, have used the Company’s proprietary AI enabled precision medicine platform to identify 59 repurposing drug candidates that could be used to develop new therapeutic strategies to increase the survival rate of patients who develop sepsis while suffering from severe COVID-19. The new study, released on Biorxiv sought to identify genetic risk factors for sepsis especially in the context of COVID-19, and to use these insights to identify existing....
A group of researchers based at Rothamsted Research have responded to a request from the White House, Microsoft, Mark Zuckerberg and others to find a way to rapidly sift through the mountain of COVID-19 scientific data. Taking time off from their own research, the Rothamsted team repurposed a tool they had originally developed to help crop scientists, to provide medical researchers with quick and intuitive access to all documented linkages between genes, medicines, and the virus....
Thermo Fisher Scientific Inc., the world leader in serving science, has announced it is expanding capacity for viral vector development and manufacturing services with construction of a new commercial manufacturing site in Plainville, Mass. The $180 million project will more than double the company's commercial viral vector capacity to support increasing demand for the development and manufacture of gene therapies and vaccines....
For use in advanced medical research into inflammation, oncology and nephritis the 7T PET-MR imaging system from MR Solutions provides a combination of PET and MRI images either simultaneously or separately. This ground breaking combination technology allows researchers to have superior soft tissue contrast and molecular imaging together.
The newly launched Version 2 Verification Panel, and Reference Material Kit, offer expanded genome coverage over the products first launched in March to now include the S gene region. As testing priorities shift from molecular to serological, LGC SeraCare also plans to expand their product offering to antibody controls in continued support of public health efforts against COVID-19. LGC SeraCare’s proprietary AccuPlex technology mimics wild-type pathogenic viruses, but is safe, non-infectious, and replication deficient...
U.S. Food and Drug Administration (FDA) has provided Emergency Use Authorization (EUA) for EUROIMMUN’s (a PerkinElmer company) Anti-SARS-CoV-2 ELISA (IgG) serology test. Clinical laboratories certified to perform high complexity tests under Clinical Laboratory Improvement Amendments (CLIA) can immediately begin using this ELISA for the detection of antibodies of the immunoglobulin class G....
Analysis work from the MRC-University of Glasgow Centre for Virus Research provides evidence that SARS-CoV-2, the virus that causes COVID-19, has not mutated into different types. Recent research had suggested that more than one type of SARS-CoV-2 was now circulating in the pandemic, with one strain being more aggressive and causing more serious illness than the other. Now, using analysis of SARS-CoV-2 virus samples from the pandemic, scientists have been able to show that only one type of the virus is currently circulating....
The Liverpool Good Clinical Practice Laboratory (GCPLab) Facility directed by Professor Bill Greenhalf, has a crucial role in supporting the International Severe Acute Respiratory and Emerging Infection Consortium - Coronavirus Clinical Characterisation Consortium (ISARIC-4C) run the Clinical Characterisation Protocol UK (CCP-UK) led by Professor Calum Semple in Liverpool, Dr Kenneth Baillie in Edinburgh and Professor Peter Openshaw at Imperial College London....
To accelerate national, multi-institutional efforts focused on mapping coronavirus transmission and epidemiological studies, Thermo Fisher Scientific announces the SARS-CoV-2 GlobalAccess Sequencing Program for research consortia and industry groups battling the spread of the pandemic globally. Under the program, the company will provide 50 units of the Ion Torrent Genexus System at a subsidized price to support global collaborative COVID-19 research....
More than a century after giving the world aspirin, another potential drug has been found in the stem and leaves of willows – this time with anti-cancer properties. Scientists led from Rothamsted Research, working with cancer biologists at the University of Kent have discovered the chemical, miyabeacin, which has been found to kill various cancer cells, including those resistant to other drugs....
Merck, a leading science and technology company, has announced a second Carlsbad, California, U.S.A.-based facility for its BioReliance® viral and gene therapy service offering. The new, € 100 million commercial facility is expected to open next year. “Viral vector manufacturing has transitioned from a niche industry to the cornerstone of the future of biopharmaceuticals,” said Udit Batra, member of the Merck Executive Board and CEO, Life Science....
The University of Oxford has announced an agreement with the UK-based global biopharmaceutical company AstraZeneca for the further development, large-scale manufacture and potential distribution of the COVID-19 vaccine candidate currently being trialled by the University. The partnership is to begin immediately with the final terms being agreed in the coming weeks. This will allow for rapid vaccination around the world if the COVID-19 vaccine candidate proves to be effective....
A wholistic tumour sampling method that more accurately detects genetic alterations in tumours, which are critical in allowing treatment to be personalised to each and every patient, has been developed by researchers from the Crick, Roche and The Royal Marsden NHS Foundation Trust and published in Cell Reports. To help doctors select treatment options for cancer patients, a sample from their tumour can be DNA sequenced....
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has entered into a collaboration with Cytiva, formerly known as GE Healthcare Life Sciences. The companies will develop and manufacture an Affimer-based point-of-care rapid test intended for screening of large populations to diagnose the COVID-19 coronavirus infection. The World Health Organisation recently....
Fully inclusive and managed RBDS uses Bioquell’s 35% hydrogen peroxide vapour solution to eliminate pathogens, providing a 6-log sporicidal kill. With the number of COVID-19 cases rising globally, Bioquell, a leading manufacturer of high-performance bio-decontamination systems, is offering a proven solution to help eradicate coronavirus in a range of healthcare, life sciences and pharmaceutical environments, including isolation rooms and public spaces....
With years of experience in providing quality contract research services, Profacgen has accumulated experience in virtually all aspects of protein development and protein production. Now, scientists have access to Profacgen’s recently released Trimeric Protein Production Service, generating new insights into the assembly and maturation of trimers that will have implications for the design of effective vaccines....
If you have ever tried to measure formaldehyde by GC using an FID, you will have noticed that the response you get is significantly lower than you might have expected. The flame ionization detector (FID) is the most widely used detector in gas chromatography. It is extremely sensitive with a wide linear range for most organic compounds. However, compounds such as oxygenates, ethers, amides and other organic compounds containing heteroatoms (e.g. O, N, S, Cl, Si), generate a lower or sometimes negligible response....
The accurate identification of biomarkers in biological samples – such as volatiles in breath, saliva and urine – has the potential to provide rapid, minimally-invasive disease diagnosis. However, diagnostic compounds are rarely of high abundance in these complex matrices, so a sensitive and comprehensive approach is required to discover the maximum number of compounds in a realistic run time. Attend this free-of-charge webinar...
Looking for new ways to test your knowledge during the lockdown? Leading global supplier of research materials, Goodfellow, has recently updated its Mr. Material game, a free educational app which tests the extent of your periodic table knowledge. Mr. Material was originally created to celebrate the 150th anniversary of Mendeleev’s periodic table, an iconic and vital tool for anybody in the scientific community, whether you’re a student, researcher, teacher or just have a general interest in science....
OXGENE™ and The Native Antigen Company have announced a collaboration to scale up production of SARS-CoV-2 (COVID-19) reagents by combining OXGENE’s proprietary Adenoviral Protein Machine Technology with The Native Antigen Company’s antigen development expertise. Together, OXGENE and The Native Antigen Company will aim to scale their antigen manufacturing capabilities to deliver high-purity, recombinant proteins for the development of diagnostics and vaccines...
Thermo Fisher Scientific Inc., has announced that the U.S. Food and Drug Administration (FDA) has further expanded emergency use authorization (EUA) for its multiplex real-time PCR test intended for the qualitative detection of nucleic acid from SARS?CoV?2, the virus that causes COVID-19. "Increasing COVID-19 testing is a top priority in re-opening global economies," said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific....
The Wyss Institute for Biologically Inspired Engineering at Harvard University and Cytosurge AG, a company manufacturing unique high-precision nanotechnology instruments, have announced that they will collaboratively investigate CRISPR-based approaches to more effectively introduce multiple edits into the genome of single cells, while minimizing CRISPR-related toxicity. This capability could become instrumental in driving forward diverse large-scale efforts such as...
Data scientists from UK-headquartered AI precision medicine company, PrecisionLife, have used the Company’s proprietary AI enabled precision medicine platform to identify 59 repurposing drug candidates that could be used to develop new therapeutic strategies to increase the survival rate of patients who develop sepsis while suffering from severe COVID-19. The new study, released on Biorxiv sought to identify genetic risk factors for sepsis especially in the context of COVID-19, and to use these insights to identify existing....
A group of researchers based at Rothamsted Research have responded to a request from the White House, Microsoft, Mark Zuckerberg and others to find a way to rapidly sift through the mountain of COVID-19 scientific data. Taking time off from their own research, the Rothamsted team repurposed a tool they had originally developed to help crop scientists, to provide medical researchers with quick and intuitive access to all documented linkages between genes, medicines, and the virus....
For use in advanced medical research into inflammation, oncology and nephritis the 7T PET-MR imaging system from MR Solutions provides a combination of PET and MRI images either simultaneously or separately. This ground breaking combination technology allows researchers to have superior soft tissue contrast and molecular imaging together.
The newly launched Version 2 Verification Panel, and Reference Material Kit, offer expanded genome coverage over the products first launched in March to now include the S gene region. As testing priorities shift from molecular to serological, LGC SeraCare also plans to expand their product offering to antibody controls in continued support of public health efforts against COVID-19. LGC SeraCare’s proprietary AccuPlex technology mimics wild-type pathogenic viruses, but is safe, non-infectious, and replication deficient...
U.S. Food and Drug Administration (FDA) has provided Emergency Use Authorization (EUA) for EUROIMMUN’s (a PerkinElmer company) Anti-SARS-CoV-2 ELISA (IgG) serology test. Clinical laboratories certified to perform high complexity tests under Clinical Laboratory Improvement Amendments (CLIA) can immediately begin using this ELISA for the detection of antibodies of the immunoglobulin class G....
Analysis work from the MRC-University of Glasgow Centre for Virus Research provides evidence that SARS-CoV-2, the virus that causes COVID-19, has not mutated into different types. Recent research had suggested that more than one type of SARS-CoV-2 was now circulating in the pandemic, with one strain being more aggressive and causing more serious illness than the other. Now, using analysis of SARS-CoV-2 virus samples from the pandemic, scientists have been able to show that only one type of the virus is currently circulating....
The Liverpool Good Clinical Practice Laboratory (GCPLab) Facility directed by Professor Bill Greenhalf, has a crucial role in supporting the International Severe Acute Respiratory and Emerging Infection Consortium - Coronavirus Clinical Characterisation Consortium (ISARIC-4C) run the Clinical Characterisation Protocol UK (CCP-UK) led by Professor Calum Semple in Liverpool, Dr Kenneth Baillie in Edinburgh and Professor Peter Openshaw at Imperial College London....
More than a century after giving the world aspirin, another potential drug has been found in the stem and leaves of willows – this time with anti-cancer properties. Scientists led from Rothamsted Research, working with cancer biologists at the University of Kent have discovered the chemical, miyabeacin, which has been found to kill various cancer cells, including those resistant to other drugs....
Merck, a leading science and technology company, has announced a second Carlsbad, California, U.S.A.-based facility for its BioReliance® viral and gene therapy service offering. The new, € 100 million commercial facility is expected to open next year. “Viral vector manufacturing has transitioned from a niche industry to the cornerstone of the future of biopharmaceuticals,” said Udit Batra, member of the Merck Executive Board and CEO, Life Science....
The University of Oxford has announced an agreement with the UK-based global biopharmaceutical company AstraZeneca for the further development, large-scale manufacture and potential distribution of the COVID-19 vaccine candidate currently being trialled by the University. The partnership is to begin immediately with the final terms being agreed in the coming weeks. This will allow for rapid vaccination around the world if the COVID-19 vaccine candidate proves to be effective....
A wholistic tumour sampling method that more accurately detects genetic alterations in tumours, which are critical in allowing treatment to be personalised to each and every patient, has been developed by researchers from the Crick, Roche and The Royal Marsden NHS Foundation Trust and published in Cell Reports. To help doctors select treatment options for cancer patients, a sample from their tumour can be DNA sequenced....
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has entered into a collaboration with Cytiva, formerly known as GE Healthcare Life Sciences. The companies will develop and manufacture an Affimer-based point-of-care rapid test intended for screening of large populations to diagnose the COVID-19 coronavirus infection. The World Health Organisation recently....
Fully inclusive and managed RBDS uses Bioquell’s 35% hydrogen peroxide vapour solution to eliminate pathogens, providing a 6-log sporicidal kill. 
With years of experience in providing quality contract research services, Profacgen has accumulated experience in virtually all aspects of protein development and protein production. 
If you have ever tried to measure formaldehyde by GC using an FID, you will have noticed that the response you get is significantly lower than you might have expected. The flame ionization detector (FID) is the most widely used detector in gas chromatography. It is extremely sensitive with a wide linear range for most organic compounds. However, compounds such as oxygenates, ethers, amides and other organic compounds containing heteroatoms (e.g. O, N, S, Cl, Si), generate a lower or sometimes negligible response....
The accurate identification of biomarkers in biological samples – such as volatiles in breath, saliva and urine – has the potential to provide rapid, minimally-invasive disease diagnosis. However, diagnostic compounds are rarely of high abundance in these complex matrices, so a sensitive and comprehensive approach is required to discover the maximum number of compounds in a realistic run time. Attend this free-of-charge webinar...
Looking for new ways to test your knowledge during the lockdown? Leading global supplier of research materials, Goodfellow, has recently updated its Mr. Material game, a free educational app which tests the extent of your periodic table knowledge. Mr. Material was originally created to celebrate the 150th anniversary of Mendeleev’s periodic table, an iconic and vital tool for anybody in the scientific community, whether you’re a student, researcher, teacher or just have a general interest in science....
OXGENE™ and The Native Antigen Company have announced a collaboration to scale up production of SARS-CoV-2 (COVID-19) reagents by combining OXGENE’s proprietary Adenoviral Protein Machine Technology with The Native Antigen Company’s antigen development expertise. Together, OXGENE and The Native Antigen Company will aim to scale their antigen manufacturing capabilities to deliver high-purity, recombinant proteins for the development of diagnostics and vaccines...